You are here

MMPA: A Novel Multiplexing Methylation Analysis Technology

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R44CA134258-01
Agency Tracking Number: CA134258
Amount: $219,350.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Timeline
Solicitation Year: 2008
Award Year: 2008
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
GLC BIOTECHNOLOGY, INC. 7362 STOCKWOOD DRIVE
SOLON, OH 44139
United States
DUNS: 144259343
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 () -
Business Contact
Phone: (440) 666-2844
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): This fast-track SBIR project is to develop a novel multiplexed methylation profiling assay (MMPA) technology for methylation analysis of DNA derived from clinical specimens. Specifically, we will develop the MMPA assays
(one for each type of cancer) for analysis of DNA methylation in colorectal, lung, and breast cancer, the three deadliest cancers, respectively. Each assay can simultaneously determine the methylation status of 20 genes in a 10,000 fold excess of unmethyl
ated DNA. The assays can also determine the degree of methylation and the relative abundance of methylated genes in clinic specimens. In addition, the assays will be cost-effective and easy to operate. The goal of Phase I is to determine if the MMPA assay
can accurately reveal methylation in DNA derived from clinic samples. Experimentally, we will use our existing MMPA assay to profile the methylation status of eight genes in DNA derived from stools, the most complex specimen. The specific milestone is to d
emonstrate that this assay can achieve the detection sensitivity and specificity of 90% or better, respectively. Phase II is to develop the MMPA assays for analysis of DNA methylation in colorectal, lung, and breast cancers, respectively. Each MMPA assay
fires one shot to kill four birds . First, the assay can determine the methylation status of an individual gene; second, the assay profiles DNA methylation among a number of genes; third, the assay has the capability of determining the degree of methylat
ion of methylated genes; and fourth, the assay provides insights into the abundance of methylated genes in clinical specimens. Clearly, these unique features will make MMPA the method of choice for methylation analysis, and thus the success of this project
will have a profound impact on both cancer screening and basic cancer research.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government